


G-CSF (Granulocyte Colony Stimulating Factors) Market Driven By Increasing Prevalence Of Cancer

The Business Research Company's G-CSF (Granulocyte Colony Stimulating Factors) Global Market Report 2020-30: COVID-19 Growth And Change

LONDON, GREATER LONDON, UK, February 1, 2021 /EINPresswire.com/ -- New year, new updates! Our reports have been revised for market size, forecasts, and strategies to take on 2021 after the COVID-19 impact: <https://www.thebusinessresearchcompany.com/global-market-reports>



G-CSF (Granulocyte Colony Stimulating Factors) Global Market Report 2020-30: COVID-19 Growth And Change

The increasing prevalence of cancer is a key factor driving the growth of the [global G-CSF market](#). Cancer is considered to be the second major cause of death, with around 1 in 6 deaths worldwide being due to cancer. According to the World Health Organization (WHO), 9.6 million deaths occurred in 2018 due to cancer. About 70% of deaths from cancer occur in low- and middle-income countries. G-CSF is a class of growth factor which produces white blood cells in the bone marrow to minimize the risk of infection and sepsis. In cancer patients, G-CSF accelerates recovery and reduces mortality from neutropenia after chemotherapy for cancer. It can also reduce infection after certain forms of treatment for cancer. Therefore, the increasing prevalence of cancer is expected to drive the growth of the granulocyte colony stimulating factor market. North America accounts for the largest share in the market, with Asia-Pacific expected to be the fastest-growing region in the forecast period.

The [global granulocyte-colony stimulating factor \(G-CSF\) market](#) was expected to decline from \$7.30 billion in 2019 to \$6.91 billion in 2020 at a compound annual growth rate (CAGR) of -5.27%. The decline was mainly due to the COVID-19 outbreak that has led to restrictive containment measures involving social distancing, remote working, and the closure of industries and other commercial activities resulting in operational challenges. The entire supply chain has been disrupted, impacting the market negatively. The granulocyte colony stimulating factor drugs market is expected to recover and reach \$8.33 billion in 2023 at a CAGR of 6.44%.

Here Is A List Of Similar Reports By The Business Research Company:

Neutropenia Biologic Drug Treatment Global Market Report 2020-30: COVID-19 Growth And Change

<https://www.thebusinessresearchcompany.com/report/neutropenia-biologic-drug-treatment-global-market-report-2020-30-covid-19-growth-and-change>

Pegfilgrastim Biosimilars Market - By Application (Chemotherapy Induced Neutropenia, Transplantation, Others), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Mail Order/Online Pharmacies), And By Region, Opportunities And Strategies – Global Pegfilgrastim Biosimilars Market Forecast To 2030

<https://www.thebusinessresearchcompany.com/report/pegfilgrastim-biosimilars-market>

Oncology Drugs Market - By Type (Blood Cancer, Breast Cancer, Lung Cancer, Prostate cancer, Colorectal Cancer, Cervical cancer, Kidney cancer, Gastric Cancer, Brain Tumor, Skin Cancer, Ovarian Cancer, Bladder Cancer, Pancreatic Cancer, Thyroid cancer, Others), By Drug Class Type (Targeted Therapy, Immunotherapy (Biologic Therapy), Chemotherapy, Hormonal Therapy), By Distribution Channel (Retail Pharmacies/Drug Stores, Hospital Pharmacies, Others), By Route Of Administration (Oral, Parenteral, Others), By Drug Classification (Branded, Generic), And By Region, Opportunities And Strategies - Global Forecast To 2030

<https://www.thebusinessresearchcompany.com/report/oncology-drugs-market>

Interested to know more about [The Business Research Company?](#)

The Business Research Company is a market intelligence firm that excels in company, market, and consumer research. Located globally it has specialist consultants in a wide range of industries including manufacturing, healthcare, financial services, chemicals, and technology.

Oliver Guirdham

The Business Research Company

+44 20 7193 0708

info@tbrc.info

Visit us on social media:

[Facebook](#)

[Twitter](#)

[LinkedIn](#)

This press release can be viewed online at: <https://www.einpresswire.com/article/535126092>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

